The Role of Neurofilament Light (NfL) in Patients With Hydrocephalus
Key facts
- Who runs it
- University Hospital Hradec Kralove
- Where
- Czechia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 41 people enrolled
- Started
- 7 Dec 2023
- Ended
- 27 Sept 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Lumbar puncture
- External lumbar drainage
- Lumbar infusion test
- Ventriculo-peritoneal shunt placement
- General Anesthesia
- Prechamber puncture
- Blood sampling #1
- Blood sampling #2
- Blood sampling #3
- Blood sampling #4 and #5
- Record updated
- 2 October 2025
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- In group A:; Patients with diagnosed communicating hydrocephalus; MMSE > 10 points; Absence of any structural laesion on MRI or CT; Accepted Informed consent
- In group B:; MMSE > 10 points; Absence of any structural laesion on MRI or CT; Accepted Informed consent; Elective spinal surgery without affecting dural sac and the spinal cord; Surgery shorter than 120 minutes of lasting the general anesthesia
Who cannot take part
- Surgery lasting more than 120 minutes
- Pre-existing other type of demetia (m. Alzheimer, vascular dementia)
- Non-communicating hydrocephalus
- Structural laesion on MRI or CT (tumour, contusion, aneurysm)
- MMSE < 10 points
- Life-expectancy shorter than 1 year
- Blood loss more than 500 ml
- Opening of dural sac (liquororhea)
- Adverse events during general anestesia: MAP<60 mm Hg more than 5 minutes, arythmia with need for farmacological treatment
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Neurofilament Light Chain Protein (NfL) has been found by many studies as a sensitive biomarker of neuronal damage from several reasons, e.g. neurodegenerative diseases (Alzheimer's disease, Multiple Sclerosis, etc.), inflamation (HIV) or trauma. Its role as biomarker thus offers a possibility to predict and manage diseases associated with neuronal damage. Therefore our aim is to investigate the changes in level of NfL in hydrocephalus and to find its role in management of treatment in hydrocephalus.
The 2 groups in the trial
- Study group ATreatment being tested
Patients with diagnosed hydrocephalus undergoing surgery (VP shunt placement) in general anestezia. Before surgery patients undergo lumbar puncture or external lumbar drainage placement to confirmate the diagnosis and responsivity to VP shunt placement.
Treatment: Lumbar puncture, External lumbar drainage, Lumbar infusion test, Ventriculo-peritoneal shunt placement, General Anesthesia, Prechamber puncture, Blood sampling #1, Blood sampling #2, Blood sampling #3, and Blood sampling #4 and #5
- Study group BExisting treatment, for comparison
Patients without diagnosed hydrocephalus undergoing short spinal surgery without affecting dural sac (e.g. anterior cervical discectomy and fusion or lumbar disc herniation or lumbar decompression) in general anestezia.
Treatment: General Anesthesia, Blood sampling #1, Blood sampling #2, and Blood sampling #3
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Role of Neurofilament Light (NfL) in Management of Patients With Hydrocephalus: A Pilot Study
- Record updated
- 2 October 2025